Tags

Type your tag names separated by a space and hit enter

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Vaccine. 2013 Aug 02; 31(35):3594-602.V

Abstract

BACKGROUND

Unlike free polysaccharide vaccines, pneumococcal polysaccharide conjugate vaccines (PCVs) induce a T cell-dependent immune response and have the potential to provide an extended duration of protection with repeated vaccinations.

METHODS

This was an extension of a previous study in pneumococcal vaccine-naïve adults aged 50-64 years in which adults 60-64 years of age were given 13-valent PCV (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) and adults aged 50-59 were given PCV13. In this follow up study conducted about 4 years later, the 60-64 year olds initially given PCV13 received PCV13 or PPSV23, and those initially given PPSV23 received another PPSV23. All adults aged 50-59 years were re-vaccinated with PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after vaccination.

RESULTS

A second PCV13 given about 4 years after a first vaccination induced OPA titers that were significantly higher than those following the initial vaccination for 7 of 13 serotypes in the older group, and 6 of 13 serotypes in the younger group, and responses to the remaining serotypes were largely non-inferior. In contrast, OPA titers following revaccination with PPSV23 were statistically significantly lower for 9 of the 13 serotypes, and non-inferior for the remaining serotypes, when compared to the responses to the first PPSV23. OPA titers in the older adults who received PPSV23 after initial PCV13 were significantly higher than those following a first PPSV23 for 10 of the 13 serotypes.

CONCLUSION

In adults 50 to 64 years of age, initial vaccination with PCV13 establishes an immune state that results in recall anti-pneumococcal responses upon subsequent vaccination with either conjugated or free polysaccharide vaccine. In contrast, initial vaccination with PPSV23 results in an immune state in which subsequent PPSV23 administration yields generally lower responses compared with the initial responses.

Authors+Show Affiliations

The Group Health Research Institute, Group Health, Seattle, Washington, United States. jackson.l@ghc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23688525

Citation

Jackson, Lisa A., et al. "Influence of Initial Vaccination With 13-valent Pneumococcal Conjugate Vaccine or 23-valent Pneumococcal Polysaccharide Vaccine On Anti-pneumococcal Responses Following Subsequent Pneumococcal Vaccination in Adults 50 Years and Older." Vaccine, vol. 31, no. 35, 2013, pp. 3594-602.
Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594-602.
Jackson, L. A., Gurtman, A., van Cleeff, M., Frenck, R. W., Treanor, J., Jansen, K. U., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013). Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine, 31(35), 3594-602. https://doi.org/10.1016/j.vaccine.2013.04.084
Jackson LA, et al. Influence of Initial Vaccination With 13-valent Pneumococcal Conjugate Vaccine or 23-valent Pneumococcal Polysaccharide Vaccine On Anti-pneumococcal Responses Following Subsequent Pneumococcal Vaccination in Adults 50 Years and Older. Vaccine. 2013 Aug 2;31(35):3594-602. PubMed PMID: 23688525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. AU - Jackson,Lisa A, AU - Gurtman,Alejandra, AU - van Cleeff,Martin, AU - Frenck,Robert W, AU - Treanor,John, AU - Jansen,Kathrin U, AU - Scott,Daniel A, AU - Emini,Emilio A, AU - Gruber,William C, AU - Schmoele-Thoma,Beate, Y1 - 2013/05/18/ PY - 2013/01/04/received PY - 2013/04/11/revised PY - 2013/04/26/accepted PY - 2013/5/22/entrez PY - 2013/5/22/pubmed PY - 2014/4/9/medline KW - 13-valent pneumococcal conjugate vaccine KW - 23-valent polysaccharide vaccine KW - ACIP KW - AE KW - Adult KW - CI KW - CRM(197) KW - GMR KW - GMT KW - OPA KW - PCV KW - PCV13 KW - PPSV23 KW - Pneumococcal conjugate vaccine KW - RCDC KW - Recall responses KW - SAE KW - United States Advisory Committee on Immunization Practices KW - adverse event KW - confidence interval KW - cross-reactive material 197 KW - geometric mean ratio KW - geometric mean titer KW - opsonophagocytic activity KW - pneumococcal polysaccharide conjugate vaccine KW - reverse cumulative distribution curve KW - serious adverse event SP - 3594 EP - 602 JF - Vaccine JO - Vaccine VL - 31 IS - 35 N2 - BACKGROUND: Unlike free polysaccharide vaccines, pneumococcal polysaccharide conjugate vaccines (PCVs) induce a T cell-dependent immune response and have the potential to provide an extended duration of protection with repeated vaccinations. METHODS: This was an extension of a previous study in pneumococcal vaccine-naïve adults aged 50-64 years in which adults 60-64 years of age were given 13-valent PCV (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) and adults aged 50-59 were given PCV13. In this follow up study conducted about 4 years later, the 60-64 year olds initially given PCV13 received PCV13 or PPSV23, and those initially given PPSV23 received another PPSV23. All adults aged 50-59 years were re-vaccinated with PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after vaccination. RESULTS: A second PCV13 given about 4 years after a first vaccination induced OPA titers that were significantly higher than those following the initial vaccination for 7 of 13 serotypes in the older group, and 6 of 13 serotypes in the younger group, and responses to the remaining serotypes were largely non-inferior. In contrast, OPA titers following revaccination with PPSV23 were statistically significantly lower for 9 of the 13 serotypes, and non-inferior for the remaining serotypes, when compared to the responses to the first PPSV23. OPA titers in the older adults who received PPSV23 after initial PCV13 were significantly higher than those following a first PPSV23 for 10 of the 13 serotypes. CONCLUSION: In adults 50 to 64 years of age, initial vaccination with PCV13 establishes an immune state that results in recall anti-pneumococcal responses upon subsequent vaccination with either conjugated or free polysaccharide vaccine. In contrast, initial vaccination with PPSV23 results in an immune state in which subsequent PPSV23 administration yields generally lower responses compared with the initial responses. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/23688525/Influence_of_initial_vaccination_with_13_valent_pneumococcal_conjugate_vaccine_or_23_valent_pneumococcal_polysaccharide_vaccine_on_anti_pneumococcal_responses_following_subsequent_pneumococcal_vaccination_in_adults_50_years_and_older_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(13)00586-0 DB - PRIME DP - Unbound Medicine ER -